ES-014

N/A

Report date: 2026/04/30 20:00:20
First In Class

Base Information

Drug NameES-014
Drug Alias NameES-014
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Ectonucleoside triphosphate diphosphohydrolase 1Anti-TGF-β
TargetsEctonucleoside triphosphate diphosphohydrolase 1Transforming growth factor beta
Therapy Area/IndicationsSolid tumoursFibromatosis, AggressiveNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesElpiscience (Shanghai) Biopharma Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesElpiscience (Shanghai) Biopharma LtdElpiscience (Suzhou) Biopharma Ltd
Inactive CompaniesElpiscience Biopharma Ltd
Active IndicationsSolid tumoursFibromatosis, Aggressive
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A